Skip to main content

Table 1 Characteristics of patients with candidaemia and univariate analysis for all cause 30-day mortality

From: Candidaemia and a risk predictive model for overall mortality: a prospective multicentre study

 

No. patients (total = 133)

30-day mortality

Odds ratio, 95% confidence interval

P value

Age > 65 years

57 (43)

24 (42)

2.7 (1.3–5.8)

0.01

Male gender

76 (57)

24 (32)

1.1 (0.5–2.3)

0.8

Female gender

57 (43)

17 (30)

0.9 (0.4–1.9)

0.8

Setting of candidaemia

 IHCA

113 (85)

35 (31)

1 .0 (0.4–3.0)

0.9

 OHCA

13 (10)

3 (23)

0.6 (0.2–2.5)

0.6

 CA

7 (5)

3 (43)

0.6 (0.2–2.5)

0.5

Admitting service

 Medical

77 (58)

30 (39)

2.6 (1.2–5.8)

0.02

 Surgical

56 (42)

11 (20)

0.4 (0.2–0.8)

0.02

 ICU admission

55 (41)

22 (40)

2.1 (1.0–4.4)

0.06

Co-morbidities

 Haematologic malignancy

20 (15)

10 (50)

2.6 (1.0–7.0)

0.06

 Allogeneic stem cell transplantation

2 (1)

1 (50)

2.3 (0.1–37.3)

0.6

 Solid organ malignancy

25 (19)

7 (28)

0.8 (0.3–2.2)

0.7

 Solid organ transplantation

5 (4)

1 (20)

0.5 (0.1–5.0)

0.6

 Diabetes mellitus

33 (25)

10 (30)

1.0 (0.4–2.3)

0.9

 Chronic organ dysfunction

50 (38)

29 (58)

0.4(0.2–0.9)

0.03

 Renal disease

18 (14)

8 (44)

2.0 (0.7–5.5)

0.2

 Liver disease

15 (11)

5 (33)

1.1 (0.4–3.6)

0.8

 Cardiovascular disease

26 (20)

11 (42)

1.8 (0.8–4.6)

0.2

 Respiratory disease

11 (8)

5 (45)

2.0 (0.6–6.9)

0.3

Predisposing factors

 Surgery

69 (52)

16 (23)

0.5 (0.2–1.0)

0.05

 Gastrointestinal surgery

35 (26)

11 (31)

1.0 (0.4–2.4)

0.9

 Urinary catheter

80 (60)

15 (19)

1.6 (0.7–3.6)

0.2

 CVAD

98 (74)

30 (31)

1.0 (0.4–2.2)

0.9

 Hyperalimentation

27 (20)

5 (19)

0.4 (0.2–1.3)

0.1

 Corticosteroids or other immunosuppressant

36 (27)

13 (36)

1.4 (0.6–3.1)

0.4

 Intravenous drug use

13 (10)

1 (8)

0.2 (0.02–1.3)

0.1

 Use of antibiotic agents ≥10 days

39 (29)

16 (41)

1.9 (0.9–4.2)

0.1

 Prior antifungal usea

19 (14)

7 (37)

1.4 (0.5–3.8)

0.5

 Sepsis syndrome

97 (73)

29 (30)

0.9 (0.4–1.9)

0.5

Source of candidaemia

 Intravascular

42 (32)

9 (21)

0.5 (0.2–1.2)

0.1

 Gastrointestinal

46 (35)

19 (41)

2.1 (1.0–4.4)

0.06

 Urologic

27 (20)

2 (7)

0.1 (0.03–0.6)

0.009

 Unknown

18 (14)

11 (61)

4.4 (1.6–12.5)

0.005

Candida species

 Candida albicans

52 (39)

17 (33)

1.2 (0.5–2.4)

0.7

 Candida glabrata complex

43 (32)

15 (35)

1.4 (0.5–3.8

0.5

 Candida parapsilosis complex

13 (10)

1 (8)

0.2 (0.02–1.3)

0.09

 Other Candida species b

25 (19)

8 (32)

1.1 (0.4–2.7)

0.9

  1. Counts are shown as n (%) unless otherwise stated
  2. CA community acquired, CVAD Central venous access device, IHCA inpatient healthcare associated, ICU intensive care unit, OHCA outpatient healthcare associated
  3. a Antifungals used prior to diagnosis of candidaemia included fluconazole in 15 patients, voriconazole in 1, anidulafungin in 1, caspofungin as prophylaxis in 2 and voriconazole for treatment of possible pulmonary aspergillosis in 1
  4. b C. tropicalis (n = 10), C, krusei (n = 5), C. robusta (n = 1), C. dubliniensis (n = 1), C. lipolytica (n = 1), C. lusitaniae (n = 1), more than 1 Candida spp. (n = 6); these were C. albicans and C. glabrata sensu stricto (n = 2), C. albicans and C. bracariensis (n = 1), C. albicans and C. nivariensis (n = 1), C. albicans and C. parapsilosis sensu stricto (n-1), and C. albicans,C. parapsilosis sensu stricto and C. tropicalis (n = 1)
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us